Study of K-1728 for advanced solid tumors with PIK3CA mutation
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests an experimental drug called K-1728 in people with advanced solid tumors that have a specific genetic change called PIK3CA. The goal is to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have been diagnosed with an advanced or metastatic solid tumor (cancer that has spread).
- Your tumor has a specific genetic change called a PIK3CA mutation.
- You are able to take care of yourself (ECOG performance status 0 or 1).
- Your organs (such as liver, kidneys, and heart) are working well enough for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called REC-7735 for people with solid tumors that have a specific genetic change (PIK3CA H1047R). The drug targets this change to try to stop the cancer from growing.
This trial tests a new drug, SNV4818, for people with advanced solid tumors that have a specific change in the PIK3CA gene. It may help when other treatments have stopped working.
This study tests a new drug called LAE118, which targets cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments for advanced solid tumors, and the goal is to see if it is safe and can help shrink tumors.
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
This trial tests an experimental drug called GenSci145, which may target cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments. The goal is to see if it can shrink tumors or slow cancer growth.
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.